HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 9.4 Linux 31MAR21:12:06:0931MAR21:12:06:09 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS TE SASDATA 9.4 Linux 31MAR21:12:06:0931MAR21:12:06:09 Trial Elements HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000000600000000000000000000 STUDYID Study Identifier DOMAIN Domain Abbreviation ETCD Element Code ELEMENT Description of Element $TESTRL Rule for Start of Element &ETEENRL Rule for End of Element J HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 C4591001TESCRN Screening Informed consent Start of treatment C4591001TESCRNOL Screening Open LabelStart of Open label consent Start of open label treatment C4591001TEVAXB1_10BNT162b1 (10 mcg) Start dose of BNT162b1 (10 mcg) Start of next dose or follow-up visit C4591001TEVAXB1_20BNT162b1 (20 mcg) Start dose of BNT162b1 (20 mcg) Start of next dose or follow-up visit C4591001TEVAXB1_30BNT162b1 (30 mcg) Start dose of BNT162b1 (30 mcg) Start of next dose or follow-up visit C4591001TEVAXB1100BNT162b1 (100 mcg) Start dose of BNT162b1 (100 mcg) Start of next dose or follow-up visit C4591001TEVAXB2_10BNT162b2 (10 mcg) Start dose of BNT162b2 (10 mcg) Start of next dose or follow-up visit C4591001TEVAXB2_20BNT162b2 (20 mcg) Start dose of BNT162b2 (20 mcg) Start of next dose or follow-up visit C4591001TEVAXB2_30BNT162b2 (30 mcg) Start dose of BNT162b2 (30 mcg) Start of next dose or follow-up visit C4591001TEVAXP Placebo Start dose of Placebo Start of next dose or follow-up visit C4591001TEFUP Follow-up Start of Follow-up Visit after Vax 224 months after end of study treatment or start of open label consentC4591001TEFUPOL Follow-up Open LabelStart of Follow-up Visit after Vax 418 months after end of study treatment